Mesenchymal stromal cells: an update.

IF 3.1 3区医学 Q2 HEMATOLOGY

Current Opinion in Hematology Pub Date : 2025-07-17 DOI:10.1097/MOH.0000000000000887

Olivia J Lee, Armand Keating

{"title":"Mesenchymal stromal cells: an update.","authors":"Olivia J Lee, Armand Keating","doi":"10.1097/MOH.0000000000000887","DOIUrl":null,"url":null,"abstract":"Purpose of review: Mesenchymal stromal cells (MSCs) are widely utilized in preclinical and clinical studies, with over 1500 clinical trials, including applications in Covid-19 treatment. This review consolidates recent advances in understanding MSC biology, mechanisms of action, and clinical utility.Recent findings: This review discusses recent progress made in understanding MSC biology, including immunomodulatory mechanisms mediated by microRNAs and long noncoding RNAs. Clinically, MSC therapies have shown promise in treating conditions like Covid-19-associated ARDS and several MSC therapeutic products have been approved. Single-cell analyses have shed light on MSC heterogeneity, revealing tissue-specific and conserved subpopulations influenced by the extracellular matrix. The FDA's updated recommendations on potency assays emphasize a holistic approach to quality control, reinforcing the need for a universal reference standard to improve reproducibility and clinical outcomes. In addition, to better understand their limited success in randomized clinical trials, we highlight the importance of a universal reference standard for MSC potency.Summary: MSCs offer significant therapeutic potential, but addressing challenges in heterogeneity and potency standardization is essential. Advances in understanding their immune properties and clinical applications provide opportunities to refine and expand their use in regenerative medicine.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOH.0000000000000887","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Mesenchymal stromal cells (MSCs) are widely utilized in preclinical and clinical studies, with over 1500 clinical trials, including applications in Covid-19 treatment. This review consolidates recent advances in understanding MSC biology, mechanisms of action, and clinical utility.

Recent findings: This review discusses recent progress made in understanding MSC biology, including immunomodulatory mechanisms mediated by microRNAs and long noncoding RNAs. Clinically, MSC therapies have shown promise in treating conditions like Covid-19-associated ARDS and several MSC therapeutic products have been approved. Single-cell analyses have shed light on MSC heterogeneity, revealing tissue-specific and conserved subpopulations influenced by the extracellular matrix. The FDA's updated recommendations on potency assays emphasize a holistic approach to quality control, reinforcing the need for a universal reference standard to improve reproducibility and clinical outcomes. In addition, to better understand their limited success in randomized clinical trials, we highlight the importance of a universal reference standard for MSC potency.

Summary: MSCs offer significant therapeutic potential, but addressing challenges in heterogeneity and potency standardization is essential. Advances in understanding their immune properties and clinical applications provide opportunities to refine and expand their use in regenerative medicine.

查看原文本刊更多论文

间充质间质细胞：一个更新。

间充质基质细胞（MSCs）广泛应用于临床前和临床研究，临床试验超过1500项，包括在Covid-19治疗中的应用。本文综述了MSC生物学、作用机制和临床应用方面的最新进展。本文综述了MSC生物学的最新进展，包括microRNAs和长链非编码rna介导的免疫调节机制。在临床上，MSC疗法在治疗covid -19相关ARDS等疾病方面显示出希望，并且已经批准了几种MSC治疗产品。单细胞分析揭示了间质干细胞的异质性，揭示了受细胞外基质影响的组织特异性和保守亚群。FDA对效价测定的最新建议强调了质量控制的整体方法，强调了对通用参考标准的需求，以提高可重复性和临床结果。此外，为了更好地理解它们在随机临床试验中的有限成功，我们强调了MSC效力的通用参考标准的重要性。摘要：间充质干细胞具有显著的治疗潜力，但解决异质性和效力标准化的挑战是必不可少的。了解其免疫特性和临床应用的进展为改进和扩大其在再生医学中的应用提供了机会。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Hematology 医学-血液学

CiteScore

6.60

自引率

3.10%

发文量

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Hematology is an easy-to-digest bimonthly journal covering the most interesting and important advances in the field of hematology. Its hand-picked selection of editors ensure the highest quality selection of unbiased review articles on themes from nine key subject areas, including myeloid biology, Vascular biology, hematopoiesis and erythroid system and its diseases.